Loading
A phase 3 trial of Intismeran autogene in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) is a phase 3 interventional study registered as NCT07513376 by Merck Sharp & Dohme LLC, with 876 participants planned, started 2026-05-04 and due to reach its primary completion in 2034-08-22. Interventions recorded: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Resectable stage I to III non-small-cell lung cancer, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Resectable stage I to III non-small-cell lung cancer, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).